Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.280,53
-0,72%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Cara Therapeutics Inc (CARA) Cara Therapeutics Inc (CARA) Notizie

Cara Therapeutics Inc

CARA
0,6843
-0,0157 (-2,24%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/4/202413:00GLOBECara Therapeutics to Present at the 23rd Annual Needham..
07/3/202413:00GLOBECara Therapeutics to Host Notalgia Paresthetica (NP) Virtual..
06/3/202422:45EDGAR2Form S-8 - Securities to be offered to employees in employee..
04/3/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:10EDGAR2Form 8-K - Current report
04/3/202422:01GLOBECara Therapeutics Announces Fourth Quarter and Full Year..
14/2/202400:50EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202423:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202423:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202423:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:01GLOBECara Therapeutics to Announce Fourth Quarter and Full Year..
05/2/202422:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:59EDGAR2Form 8-K - Current report
29/1/202421:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
22/1/202422:19EDGAR2Form 8-K - Current report
22/1/202413:00GLOBECara Therapeutics Prioritizes Late-Stage Notalgia..
18/12/202313:10EDGAR2Form 8-K - Current report
18/12/202313:00GLOBECara Therapeutics Announces Outcome from Dose-Finding Part A..
13/11/202322:28EDGAR2Form 8-K - Current report
13/11/202322:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:11EDGAR2Form 8-K - Current report
13/11/202322:01GLOBECara Therapeutics Reports Third Quarter 2023 Financial..
03/11/202321:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202312:10EDGAR2Form 8-K - Current report
02/11/202312:00GLOBECara Therapeutics Announces up to $40.0 Million Non-Dilutive..
23/10/202313:00GLOBECara Therapeutics to Announce Third Quarter 2023 Financial..
25/9/202313:00GLOBECara Therapeutics Announces Approval of KORSUVA® IV..
05/9/202313:00GLOBECara Therapeutics to Present at the H.C. Wainwright 25th..
07/8/202322:24EDGAR2Form 8-K - Current report
07/8/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202322:10EDGAR2Form 8-K - Current report
07/8/202322:01GLOBECara Therapeutics Reports Second Quarter 2023 Financial..
04/8/202323:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/8/202323:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202313:06EDGAR2Form 8-K - Current report
03/8/202313:00GLOBECara Therapeutics Appoints Helen M. Boudreau to Board of..
02/8/202313:00GLOBECara Therapeutics to Present at the Canaccord Genuity 43rd..
25/7/202322:40EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/7/202313:00GLOBECara Therapeutics to Announce Second Quarter 2023 Financial..
03/6/202300:46PRNUSPalo Alto Networks Set to S&P 500; Others to Join S&P MidCap..
01/6/202313:00GLOBECara Therapeutics to Present at the Jefferies Healthcare..
18/5/202308:00GLOBEKapruvia® (difelikefalin) recommended by England’s NICE for..
15/5/202322:01GLOBECara Therapeutics Reports First Quarter 2023 Financial..
Apertura: 0,69 Min: 0,68 Max: 0,7264
Chiusura: 0,70

La tua Cronologia

NASDAQ
CARA
Cara Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network